Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma

INTRODUCTION: Currently available second-line (2L) therapies for advanced/metastatic esophageal squamous cell carcinoma (adv/met ESCC) include the taxanes paclitaxel and docetaxel. In clinical trials, such therapies have provided only modest improvements in survival. Few studies have assessed outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Abraham, Pranav, Gricar, Joe, Zhang, Ying, Shankaran, Veena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467430/
https://www.ncbi.nlm.nih.gov/pubmed/32533533
http://dx.doi.org/10.1007/s12325-020-01394-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467430/
https://www.ncbi.nlm.nih.gov/pubmed/32533533
http://dx.doi.org/10.1007/s12325-020-01394-y

Ejemplares similares